Patents by Inventor Huiping Amy Guan
Huiping Amy Guan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11773078Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.Type: GrantFiled: May 10, 2019Date of Patent: October 3, 2023Assignee: Glaxosmithkline Intellectual Property Development LimitedInventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Huiping Amy Guan, Yan Hu, Aaron Bayne Miller, Donghui Qin, Chengde Wu, Zhiliu Zhang, Xiaojuan Lin
-
Publication number: 20220315556Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.Type: ApplicationFiled: May 10, 2019Publication date: October 6, 2022Applicant: Glaxosmithkline Intellectual Property Development LimitedInventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Huiping Amy Guan, Yan Hu, Aaron Bayne Miller, Donghui Qin, Chengde Wu, Zhiliu Zhang, Xiaojuan Lin
-
Patent number: 11040981Abstract: Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat cancer.Type: GrantFiled: October 9, 2018Date of Patent: June 22, 2021Assignee: Syros Pharmaceuticals, Inc.Inventors: David Moebius, Jason J. Marineau, Yi Zhang, Claudio Edmundo Chuaqui, Goran Malojcic, William Sinko, Huiping Amy Guan, Stephane Ciblat, Clint James, Amandine Xolin, Sylvain Bernard, Malay Doshi
-
Publication number: 20210147431Abstract: Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat cancer.Type: ApplicationFiled: October 22, 2020Publication date: May 20, 2021Inventors: David Moebius, Jason J. Marineau, Yi Zhang, Claudio Edmundo Chuaqui, Goran Malojcic, William Sinko, Huiping Amy Guan, Stephane Ciblat, Clint James, Amandine Xolin, Sylvain Bernard, Malay Doshi
-
Publication number: 20200317676Abstract: Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat cancer.Type: ApplicationFiled: October 9, 2018Publication date: October 8, 2020Applicant: Syros Pharmaceuticals, Inc.Inventors: David Moebius, Jason J. Marineau, Yi Zhang, Kathryn Austgen, Claudio Edmundo Chuaqui, Goran Malojcic, William Sinko, Huiping Amy Guan, Tracey Lodie Savoie, Stephane Ciblat, Clint James, Amandine Xolin, Sylvain Bernard, Malay Doshi
-
Publication number: 20200291018Abstract: Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat diseases, such as cancer.Type: ApplicationFiled: July 13, 2018Publication date: September 17, 2020Applicant: Syros Pharmaceuticals, Inc.Inventors: Yi ZHANG, Claudio Edmundo CHUAQUE, Goran MALOJCIC, William SINKO, Stephane CIBLAT, Clint JAMES, Huiping Amy GUAN, Jason J. MARINEAU, David MOEBIUS
-
Patent number: 10709695Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: GrantFiled: April 5, 2019Date of Patent: July 14, 2020Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Michael P. Demartino, Huiping Amy Guan
-
Publication number: 20200071326Abstract: Described herein are compounds, methods of making such compounds, compositions (e.g., pharmaceutical compositions/medicaments) that include such compounds, and methods of using such compounds to treat diseases, such as cancer.Type: ApplicationFiled: April 13, 2018Publication date: March 5, 2020Inventors: Yi Zhang, Kathryn Austgen, Claudio Chuaqui, Goran Malojcic, William Sinko, Huiping Amy Guan, Tracey Lodie Savoie
-
Publication number: 20190247382Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: ApplicationFiled: April 5, 2019Publication date: August 15, 2019Inventors: Michael P. Demartino, Huiping Amy Guan
-
Patent number: 10294236Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: GrantFiled: December 11, 2017Date of Patent: May 21, 2019Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Huiping Amy Guan, Donghui Qin, Chengde Wu, Zhen Gong, Haiying Yang, Haiyu Yu, Zhiliu Zhang
-
Patent number: 10292975Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: GrantFiled: September 28, 2018Date of Patent: May 21, 2019Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Michael P. Demartino, Huiping Amy Guan
-
Publication number: 20190022078Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: ApplicationFiled: September 28, 2018Publication date: January 24, 2019Inventors: Michael P. DEMARTINO, Huiping Amy GUAN
-
Patent number: 10111866Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: GrantFiled: January 23, 2018Date of Patent: October 30, 2018Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Michael P. Demartino, Huiping Amy Guan
-
Publication number: 20180147194Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: ApplicationFiled: January 23, 2018Publication date: May 31, 2018Inventors: Michael P. DEMARTINO, Huiping Amy GUAN
-
Publication number: 20180099976Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: ApplicationFiled: December 11, 2017Publication date: April 12, 2018Inventors: Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Huiping Amy Guan, Donghui Qin, Chengde Wu, Zhen Gong, Haiying Yang, Haiyu Yu, Zhiliu Zhang
-
Patent number: 9918974Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: GrantFiled: September 9, 2015Date of Patent: March 20, 2018Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Michael P. Demartino, Huiping Amy Guan
-
Patent number: 9879021Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: GrantFiled: September 10, 2015Date of Patent: January 30, 2018Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Huiping Amy Guan, Donghui Qin, Chengde Wu, Zhen Gong, Haiying Yang, Haiyu Yu, Zhiliu Zhang
-
Publication number: 20170340617Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: ApplicationFiled: September 9, 2015Publication date: November 30, 2017Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Michael P. DEMARTINO, Huiping Amy GUAN
-
Publication number: 20170298074Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: ApplicationFiled: September 10, 2015Publication date: October 19, 2017Inventors: Mui CHEUNG, Michael P. DEMARTINO, Hilary Schenck EIDAM, Huiping Amy GUAN, Donghui QIN, Chengde WU, Zhen GONG, Haiying YANG, Haiyu YU, Zhiliu ZHANG
-
Patent number: 9035063Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: GrantFiled: December 9, 2014Date of Patent: May 19, 2015Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Hilary Schenck Eidam, Huiping Amy Guan, Chengde Wu, Mui Cheung